IXICO plc PDMR Dealing (3669N)
29 Enero 2021 - 4:19AM
UK Regulatory
TIDMIXI
RNS Number : 3669N
IXICO plc
29 January 2021
IXICO plc
("IXICO" or the "Company")
PDMR Dealing
Issue of Equity on exercise of options
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience , announces that it has made an
application to the London Stock Exchange for the admission to
trading on AIM of 156,471 new ordinary shares of 1p each ("New
Shares") to satisfy the exercise of options by the VP Alliance
Management (PDMR).
The New Shares are expected to be admitted to trading on AIM on
5 February 2021.
Total voting rights
Application has been made for admission to trading on AIM of
156,471 New Shares. Admission of the New Shares on AIM is expected
to become effective at 8.00 a.m. on 5 February 2021, following
which there will be in total 47,292,939 ordinary shares in the
capital of the Company in issue, each carrying equal voting
rights.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in,
IXICO under the FCA's Disclosure and Transparency Rules.
T he below makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
Details of PDMR transaction
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sylke Grootoonk
--------------------------------- --------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status PDMR (VP Alliance Management)
--------------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name IXICO plc
--------------------------------- --------------------------------------
b) LEI 2138005M1F59O6HWSA97
--------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares in IXICO plc
financial instrument,
type of instrument
Identification code GB00BCLY7L40
b) Nature of the transaction Exercise of options
--------------------------------- --------------------------------------
c) Price(s) and volume(s)
--------------------- ------------
Exercise Price(s) Volume(s)
--------------------- ------------
30.5p 112,942
--------------------- ------------
34.0p 43,529
--------------------- ------------
d) Aggregated information
- Aggregated volume 1 56,471 shares
- Price 31.5p
e) Date of the transaction 5 Feburary 2021
--------------------------------- --------------------------------------
f) Place of the transaction N/A
--------------------------------- --------------------------------------
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKCBDKBKDADB
(END) Dow Jones Newswires
January 29, 2021 05:19 ET (10:19 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
